Dana Farber/Harvard Cancer Center (DF/HCC) is an inter-institutional research enterprise that unites the major clinical, population, and basic cancer research efforts of the Harvard medical and public health community. It was founded in 1998 through a formal agreement of the Dana-Farber Cancer Institute, the Harvard Medical School and Harvard School of Medicine and Public Health, and the Beth Israel Deaconess, Brigham and Women's, Children's, and Massachusetts General Hospitals. By agreement, this will be the only NCI-designated Cancer Center application from these institutions. The DF/HCC links the efforts of a large cadre of cancer scientists - currently more than 800 members with NCI grants amounting to almost $100 million in total costs-in an interlocking organizational structure designed to promote research advances that are aimed at lowering the burden of cancer. In the aggregate, Center members have extensive experience and well-recognized expertise in the three major cancer research disciplines: basic, clinical, and population science. The research of the Center is carried out in 15 disease site- and discipline-based Research Programs that cross both institutional and scientific boundaries. In addition, the Center supports 17 Core Facilities that make shared resources, dedicated to enhancing scientific efficiency, available to all Center members. The primary goal of the Center is to promote collaborative interactions that will lead to new approaches to cancer prevention, diagnosis, and treatment. For the Harvard community, its formation represents a major, new opportunity to achieve this goal.
| Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945 |
| Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37: |
| Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534 |
| Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583 |
| Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404 |
| Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917 |
| Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121 |
| Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538 |
| Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228 |
| Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609 |
Showing the most recent 10 out of 411 publications
